[Clinical evaluation of HBV, HCV and HDV serum markers in patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC)].

11 kinds of HBV, HCV and HDV serum markers were investigated in 46 patients with HCC, 48 patients with LC, and 52 controls without liver disease. The prevalence of one out of HBV or HCV or HDV markers (M) in HCC and LC was 91.3% and 95.8% respectively, significantly higher than that in controls (17.3%). Positivity of HBV-M in HCC and LC was remarkably higher than those of HCV-M and HDV-M (P < 0.05). Prevalence of HCV-M in HBV-M negative HCC and LC was 66.7% and 75.0% respectively, significantly higher than that in HBV-M positive cases (P < 0.05). Frequency of viral replication in HCC and LC was significantly higher than that in controls (P < 0.01). The co-occurrence of two or three kinds of viral markers in HCC was more prevalent than that in LC (38% vs 14%, P < 0.05). Patients with coinfection from both HBV and HDV had a significantly younger age than those infected by HBV alone or infected by HCV (more than 10 years earlier). Among HCC and LC, 36% of HBV seronegative cases had HBV DNA detectable in their serum. Our data suggest that HCC and LC have a close association with the infection of HBV HCV and HDV especially HBV. Active viral replication and coinfection of several kinds of virus play on important role in the determination of HCC or LC development, and HDV appears to provide an additional risk for HCC and LC. In HBV-M negative cases, HCV infection may be more important for HCC and LC development than HBV.